What is the efficacy of tenofovir for the treatment of HBeAg-negative hepatitis B (HBV) (Hep B)?

Updated: Jun 08, 2021
  • Author: Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF; Chief Editor: BS Anand, MD  more...
  • Print

In another report involving patients who were randomized to receive either tenofovir (300 mg once daily) or adefovir (10 mg once daily), with all eligible adefovir-treated patients being switched to tenofovir after 48 weeks, 91% of patients receiving tenofovir at 72 weeks of treatment were found to have a viral load below 400 copies/mL, [93] compared with 88% of patients in the adefovir-to-tenofovir arm. All of the adefovir-treated patients who had a viral load below 400 copies/mL at week 48 maintained a viral load below this level after switching to tenofovir. [93] Of the patients in the adefovir arm who did not achieve optimal viral response (that is, those with a viral load >400 copies/mL) by the time they switched to tenofovir, 94% had a viral load below 400 copies/mL by week 72.

Normal ALT levels at week 72 were observed in 79% of patients who initiated therapy with tenofovir and in 77% of patients who switched from adefovir to tenofovir. [93]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!